Alzinova AB (ALZ) - Total Assets
Based on the latest financial reports, Alzinova AB (ALZ) holds total assets worth Skr143.43 Million SEK (≈ $15.44 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Alzinova AB reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Alzinova AB - Total Assets Trend (2012–2025)
This chart illustrates how Alzinova AB's total assets have evolved over time, based on quarterly financial data. Check tangible net worth ratio of Alzinova AB to evaluate the tangible quality of the company's equity base.
Alzinova AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Alzinova AB's total assets of Skr143.43 Million consist of 1.5% current assets and 98.5% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0.2% |
| Accounts Receivable | Skr1.89 Million | 1.3% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr141.22 Million | 98.5% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Alzinova AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Alzinova AB.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alzinova AB's current assets represent 1.5% of total assets in 2025, a decrease from 22.6% in 2012.
- Cash Position: Cash and equivalents constituted 0.2% of total assets in 2025, down from 18.4% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 98.0% of total assets, an increase from 14.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 98.5% of total assets.
Alzinova AB Competitors by Total Assets
Key competitors of Alzinova AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Alzinova AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.11 | 2.16 | 8.80 |
| Quick Ratio | 0.11 | 2.16 | 8.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr-17.59 Million | Skr9.96 Million | Skr44.08 Million |
Alzinova AB - Advanced Valuation Insights
This section examines the relationship between Alzinova AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.51 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 7.7% |
| Total Assets | Skr143.43 Million |
| Market Capitalization | $8.00 Million USD |
Valuation Analysis
Below Book Valuation: The market values Alzinova AB's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Alzinova AB's assets grew by 7.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Alzinova AB (2012–2025)
The table below shows the annual total assets of Alzinova AB from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr143.43 Million ≈ $15.44 Million |
+7.66% |
| 2024-12-31 | Skr133.23 Million ≈ $14.34 Million |
+8.15% |
| 2023-12-31 | Skr123.19 Million ≈ $13.26 Million |
+10.36% |
| 2022-12-31 | Skr111.62 Million ≈ $12.01 Million |
+21.74% |
| 2021-12-31 | Skr91.69 Million ≈ $9.87 Million |
-9.05% |
| 2020-12-31 | Skr100.82 Million ≈ $10.85 Million |
+58.69% |
| 2019-12-31 | Skr63.53 Million ≈ $6.84 Million |
-3.87% |
| 2018-12-31 | Skr66.09 Million ≈ $7.11 Million |
+108.34% |
| 2017-12-31 | Skr31.72 Million ≈ $3.41 Million |
-4.78% |
| 2016-12-31 | Skr33.31 Million ≈ $3.58 Million |
+50.06% |
| 2015-12-31 | Skr22.20 Million ≈ $2.39 Million |
+936.44% |
| 2014-12-31 | Skr2.14 Million ≈ $230.51K |
+47.54% |
| 2013-12-31 | Skr1.45 Million ≈ $156.23K |
+29.94% |
| 2012-12-31 | Skr1.12 Million ≈ $120.23K |
-- |
About Alzinova AB
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, call… Read more